Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of giroctocogene fitelparvovec in adult men with severe hemophilia A
2024-512075-12-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of giroctocogene fitelparvovec in hemophilia A, sponsored by Pfizer. Primary endpoint: Total annualized bleeding rate. Planned start Jun 2021; status: authorised.
02
Drugs
giroctocogene fitelparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2024-512075-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512075-12-00.